Oric Pharmaceuticals, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $7.65
- 52-Week Range
- $7.23 – $14.68
- Market Cap
- $800.27M
- P/E (TTM)
- —
- EPS (TTM)
- -1.44
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.36
- PEG Ratio
- —
- Return on Equity
- -41.76%
- Return on Assets
- -26.79%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 11.09
- Debt/Equity
- 0.02
- Total Debt
- $5.96M
- Free Cash Flow
- $-80.36M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $539.66M
Market Snapshot
About
Oric Pharmaceuticals is a clinical-stage oncology biotechnology company focused on developing therapies to overcome drug resistance in cancer. The company advances precision medicines targeting cancer resistance mechanisms, including programs focused on hormone receptor-positive breast cancer and prostate cancer.